Status:
COMPLETED
Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure
Lead Sponsor:
University of Milan
Conditions:
Pulmonary Hypertension
Diastolic Heart Failure
Eligibility:
MALE
Phase:
PHASE2
PHASE3
Brief Summary
Prevalence of heart failure (HF) with left ventricular (LV) diastolic dysfunction and preserved ejection fraction (EF) (HFpEF) is increasing. Prognosis worsens with development of pulmonary vasoconstr...
Detailed Description
Heart failure (HF) with preserved left ventricular (LV) ejection fraction (EF) (HFpEF) is a public health problem and a major topic in clinical cardiology. Its prevalence, in fact, is increasing and t...
Eligibility Criteria
Inclusion
- LVEF \>50%
- sinus rhythm and stable clinical condition defined as no changes in therapeutic regimen, or hospitalization in the 6 months preceding recruitment.
- pulmonary artery systolic pressure \> 40 mm Hg,
Exclusion
- Patients receiving nitrates
- A history of pulmonary disease
- Alternative causes of PH other than cardiac-related
- Renal failure (creatinine \> 2mg/dL)
- Anemia
- Pericardial disease
- Cardiac amyloidosis
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01156636
Start Date
January 1 2006
End Date
December 1 2009
Last Update
June 15 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.